Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.79 |
| ▸ | MEN1 | O00255 | 9/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HTT | P42858 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5126252 | 0.98 | KMT2A (0.76) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL2682054 | 0.88 | KMT2A (1.00) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL29077780 | 0.83 | MEN1 (0.89) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL29556162 | 0.83 | MEN1 (0.89) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL11476205 | 0.83 | KMT2A (0.81) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL10344695 | 0.83 | MEN1 (1.00) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL29533340 | 0.83 | MEN1 (1.00) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL4555351 | 0.82 | NPC1 (0.69) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL11049956 | 0.81 | MEN1 (0.85) | KMT2AMEN1MAPTLMNAALDH1A1 | |
| SCHEMBL8830833 | 0.81 | KMT2A (0.79) | KMT2AMEN1MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| EP-0474817-B1 | BICYCLO [3.3.0]OCTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 1995-10-11 | — | — | EP | disclosed |
| US-5098462-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| US-5098466-A | Herbicides | SANDOZ LTD. (CH) | 1992-03-24 | — | — | US | disclosed |
| EP-0474817-A1 | BICYCLO 3.3.)]OCTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE. | SCHERING AG (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1991014675-A1 | BICYCLO[3.3.)]OCTANE DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-10-03 | — | — | WO | disclosed |
| EP-0219451-B1 | SEMICARBAZONES AND THIOSEMICARBAZONES | SANDOZ AG (CH) | 1991-03-20 | — | — | EP | disclosed |
| EP-0219451-A1 | Semicarbazones and thiosemicarbazones | SANDOZ AG (CH) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | KMT2A 3999/4885MEN1 1208/4885MAPT 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.